Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2024Exploration of Targeted Anti-tumor TherapyOpen Access

Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

THThomas Fritz HansenJHJonathon T. HillGTGary Tincknell

Discussion

Loading...

Member takes

Overview

Review demonstrates improved survival and pathological response with neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer, highlighting an evolving treatment landscape.

Key Points

  • To review the current clinical evidence, practical benefits, and future directions of neoadjuvant and perioperative immunotherapy strategies in resectable early-stage non-small cell lung cancer (NSCLC).
  • Literature review summarizing trials evaluating neoadjuvant and perioperative immunotherapy and chemoimmunotherapy combinations in resectable early-stage NSCLC.
  • Evaluation of biologic rationale, including T cell priming and tumor downstaging, alongside evidence from more than 20 combination regimens and large phase III clinical trials.
  • Neoadjuvant chemoimmunotherapy combinations demonstrated significant improvements in pathological response, disease-free survival, and overall survival compared to standard approaches across multiple phase III trials.
  • Variable efficacy across more than 20 neoadjuvant and perioperative combinations has led to worldwide practice shifts alongside growing treatment complexity.
  • Novel combination regimens targeting alternate immunomodulatory pathways are currently in development to expand therapeutic options in early-stage disease.

Cite This Study

Hansen et al. (2024) studied this question.

synapsesocial.com/papers/6a8a402eab4588dbccfba053https://doi.org/10.37349/etat.2024.00273
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC2024 · 6 citations
  2. 2Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses2025 · 15 citations
  3. 3[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].2024 · 1 citations
  4. 4The role of immunotherapy in resectable non-small-cell lung cancer2025
  5. 5The Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer2026